Patients in whom CMV-specific CTL were measured at one time point at least 6 months after allografting
| Group/patient no. . | Donor . | HLA allele . | CMV-specific CTL . | CMV reactivation (days after SCT) . | GVHD grade . | Follow-up (days after SCT) . | |
|---|---|---|---|---|---|---|---|
| As % of CD8+ count at peak . | Peak absolute cell count (× 105) . | ||||||
| Group 1 (recipient +/donor + for CMV) | |||||||
| 25 | V | A2 | 4.9 | 47 | 82 | III | 550 |
| 26 | S | B7 | 0.4 | 7 | ND | I | 1030 |
| 27 | S | A2; B7 | 0; 0.4 | 0; 28 | ND | I | 247 |
| 28 | S | B7 | 12.7 | 1525 | ND | II | 1029 |
| 29 | S | A2; B7 | 0.1; 1.1 | 1.6; 22 | ND | II | 1395 |
| 30 | S | A2; B7 | 1.3; 8 | 72; 442 | 42 | III | 688 |
| 31 | S | A2 | 2.5 | 117 | 47 & 139 | III | 338 |
| 32 | S | A2 | 6 | 300 | 31 | 0 | 280 |
| 33 | S | A2; B7 | ND | ND | 52 | II | 516 |
| Group 2 (recipient +/donor − for CMV) | |||||||
| 34 | V | A2; B7 | 0.1; 3.1 | 44; 1463 | 85 & 122 | II | 990 |
| 35 | S | A2 | 1.8 | 89 | 87 | 0 | 1260 |
| 36 | V | A2 | 2.7 | 25 | 55 | II | 247 |
| 37 | S | A2 | ND | ND | ND | 0 | 732 |
| Group 3 (recipient −/donor + for CMV) | |||||||
| 38 | S | A2; B7 | 1.2; 1.5 | 82; 102 | 56 & 120 | II | 337 |
| 39 | S | A2 | ND | ND | ND | 0 | 392 |
| Group/patient no. . | Donor . | HLA allele . | CMV-specific CTL . | CMV reactivation (days after SCT) . | GVHD grade . | Follow-up (days after SCT) . | |
|---|---|---|---|---|---|---|---|
| As % of CD8+ count at peak . | Peak absolute cell count (× 105) . | ||||||
| Group 1 (recipient +/donor + for CMV) | |||||||
| 25 | V | A2 | 4.9 | 47 | 82 | III | 550 |
| 26 | S | B7 | 0.4 | 7 | ND | I | 1030 |
| 27 | S | A2; B7 | 0; 0.4 | 0; 28 | ND | I | 247 |
| 28 | S | B7 | 12.7 | 1525 | ND | II | 1029 |
| 29 | S | A2; B7 | 0.1; 1.1 | 1.6; 22 | ND | II | 1395 |
| 30 | S | A2; B7 | 1.3; 8 | 72; 442 | 42 | III | 688 |
| 31 | S | A2 | 2.5 | 117 | 47 & 139 | III | 338 |
| 32 | S | A2 | 6 | 300 | 31 | 0 | 280 |
| 33 | S | A2; B7 | ND | ND | 52 | II | 516 |
| Group 2 (recipient +/donor − for CMV) | |||||||
| 34 | V | A2; B7 | 0.1; 3.1 | 44; 1463 | 85 & 122 | II | 990 |
| 35 | S | A2 | 1.8 | 89 | 87 | 0 | 1260 |
| 36 | V | A2 | 2.7 | 25 | 55 | II | 247 |
| 37 | S | A2 | ND | ND | ND | 0 | 732 |
| Group 3 (recipient −/donor + for CMV) | |||||||
| 38 | S | A2; B7 | 1.2; 1.5 | 82; 102 | 56 & 120 | II | 337 |
| 39 | S | A2 | ND | ND | ND | 0 | 392 |
For patients who were positive for both HLA A*0201 and HLA B*0702, the results for the HLA A*0201 tetramer are shown first, followed by the results for the B*0702 tetramer.